The deleterious effects of pS129 accumulation are demonstrated and a toxic role played by these aggregates are argued in favor of a toxic role played by these aggregates.
Abstract
Phosphorylated α-synuclein at S129 (pS129) is the predominant form of α-synuclein in the aggregates known as Lewy bodies (LB) and Lewy neurites (LN), the pathological hallmarks of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), collectively known as synucleinopathies. The toxic nature of these inclusions remains contentious. To improve our understanding of these aggregates and their role in the structural and functional changes observed in synucleinopathies, we combined non-invasive structural and functional MRI in awake head-fixed M83 mice with whole-brain light-sheet fluorescence microscopy (LSFM) in the same animals following a unilateral injection of either human preformed fibrils of α-synuclein (PFF) or PBS into the dorsal striatum. We developed a multimodal framework integrating the non-invasive, mesoscopic nature of MRI with the cellular-level details of LSFM to further our understanding of the underlying pathology of synucleinopathies. Using this framework, we show that four months after injection, animals injected with PFFs showed ubiquitous spread of pS129 pathology throughout the whole brain and spinal cord consistent with anatomical connectivity from the seeding region, with some structures such as the midbrain more susceptible to pS129 accumulation. Compared to controls, PFF-injected animals showed widespread atrophy as well as a decrease in functional connectivity, while evoked activity in the somatosensory/somatomotor areas in response to spontaneous paw movements showed significant hypoactivation. These cellular, structural and functional changes were significantly associated with the proportion of pS129 accumulation determined in the same animals. Our results demonstrate the deleterious effects of pS129 accumulation and argue in favor of a toxic role played by these aggregates. One Sentence Summary Awake-MRI and whole-brain light-sheet microscopy reveal pS129 involvement in brain structure, task-related activity, and functional connectivity.
A model in which α-syn oligomer spreading, amplified by aging, simultaneously disrupts the astrocyte–glutamatergic neuron axis and drives microglia into a senescent DAM-like state is proposed, and candidate gene sets for both processes are provided for further investigation of glial dysfunction in PD.
PrPC expression levels are identified as an important modulator of nigrostriatal vulnerability and neuroinflammatory phenotype in response to αSynO, supporting the hypothesis that PrPC contributes to αSynO-mediated pathogenic mechanisms.
Flavio de Souza Júnyor, F. Leser, Sarah de Souza Albuquerque et al.· Frontiers in Neuroscience· 0 citations
A genetically controlled in vivo model of LBD-like mixed proteinopathy recapitulating αSyn aggregation, tau hyperphosphorylation, Aβ accumulation, neurodegeneration, and behavioral decline is established and supports a mechanistic link between AIMP2-enhanced αSyn toxicity and secondary proteinopathies.
Doeun Kim, Hee-Tae Kim, Ji Hun Kim et al.· Cell Death & Disease· 0 citations
Results indicate α-synuclein clearance and propagation are mediated by glymphatic function and that aquaporin-4 mis-localization observed in the presence of human synucleinopathy may contribute to the development and propagation of Lewy body pathology in conditions such as Lewy body dementia and Parkinson's disease.
Molly Braun, Matthew J. Simon, Jay Jang et al.· Brain Communications· 0 citations
Overexpression of Kcnn1, a potassium channel subunit, appears to be neuroprotective in Parkinson’s Disease, and its action may have therapeutic implications.
Maria Nagy, W. Fenton, A. Horwich· Proceedings of the National...· 0 citations
The Affinity-directed PROtein Missile system is employed and targeted degradation of α-synuclein impedes the pre-formed fibril (PFF)-induced aggregation of α-synuclein in primary neurons derived from rats expressing human α-synuclein.
Bill Carton, Géraldine Gelders, Gajanan Sathe et al.· npj Parkinson's Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.